|
Indications and Dosage
Nasal
Nasal congestion Adult: As 0.05% soln: 1-2 drops in each nostril up to 6 hrly for 3 days. Child: ≥12 yr Same as adult dose. Ophthalmic Conjunctival decongestant Adult: As 0.1% soln: Instill 1-2 drops onto conjunctival sac 3-4 hrly, as needed. Ophthalmic Minor eye irritation Adult: As 0.012% soln: Instill 1-2 drops into affected eye(s) bid or tid.
Child: ≥12 yr Same as adult dose. |
|
Contraindications
Ophth: Narrow-angle glaucoma, corneal damage, acute iritis and other serious eye disease.
|
|
Special Precautions
Patient w/ CV disease, HTN, DM, hyperthyroidism, local infection or injury. Childn. Pregnancy and lactation.
|
|
Adverse Reactions
Significant: Rebound vasodilation or congestion (prolonged/frequent use).
Nervous: Nervousness, headache, drowsiness, dizziness, weakness. GI: Nausea. CV: Cardiac irregularities, HTN. Resp: Burning, stinging, sneezing, increased discharge (nasal). Endocrine: Hyperglycaemia. Ophthalmologic: Mydriasis, ocular hyperaemia, increased redness, irritation, discomfort, blurred vision, punctuate keratitis, lacrimation, increased intraocular pressure. Dermatologic: Sweating. |
|
Ophth: C
|
|
Patient Counseling Information
This drug may cause drowsiness, temporary blurred vision, and transient mydriasis, if affected, do not drive or operate machinery. Remove contact lenses prior to ophth admin and reinsert after 10-15 min.
|
|
Drug Interactions
Potentially Fatal: May cause hypertensive crisis w/ MAOI(s).
|
|
Action
Description:
Mechanism of Action: Naphazoline is an alpha adrenergic receptor agonist which causes vasoconstriction by stimulating arterioles of the conjunctiva and nasal mucosa thus reducing swelling, redness and discomfort when applied to mucous membranes. Onset: Conjunctival vasoconstriction: W/in 10 min. Duration: 2-6 hr. Pharmacokinetics: Absorption: May be absorbed systemically. |
|
Chemical Structure
 Source: National Center for Biotechnology Information. PubChem Database. Naphazoline, CID=4436, https://pubchem.ncbi.nlm.nih.gov/compound/Naphazoline (accessed on Jan. 22, 2020) |
|
Storage
Store below 25°C.
|
|
ATC Classification
S01GA01 - naphazoline ; Belongs to the class of sympathomimetics used as ophthalmologic decongestants.
R01AA08 - naphazoline ; Belongs to the class of topical sympathomimetic agents used as nasal decongestants. |
|
References
Anon. Naphazoline (Ophthalmic). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 28/09/2017. Buckingham R (ed). Naphazoline. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 28/09/2017. McEvoy GK, Snow EK, Miller J et al (eds). Naphazoline Hydrochloride (EENT). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 28/09/2017. Naphcon Solution (Alcon). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 28/09/2017. Privine Suspension/Drops (Insight Pharmaceuticals LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 28/09/2017.
|
Sign Out
